BridgeBio grabs a second priority review for the portfolio — giving Perceptive startup cause to celebrate
Just weeks after getting its first NDA in — and grabbing priority review from the FDA in the process — BridgeBio says it’s lined up a second potential speedy approval for the portfolio.
The honor goes to BridgeBio affiliate QED Therapeutics, which is developing infigratinib as a cholangiocarcinoma treatment. In particular, it had filed for approval in second- and later-line use.
It’s also good news for LianBio, the Perceptive startup boasting a new model for bringing Western drugs to China. Infigratinib is one of the anchor drugs of its in-licensed portfolio; in fact, BridgeBio CEO Neil Kumar has pointed to the program as an example of LianBio’s creative strategies in tailoring development programs for China.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.